SCHEMBL25840905

SCHEMBL25840905

Nc1cnnc2cc(-c3cc(B(O)O)ccc3-c3ccccn3)ccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.35
F12 P00748 1/20 0.35
F11 P03951 1/20 0.35
KLKB1 P03952 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
CHEK2 O96017 1/20 0.33
ALOX5AP P20292 5/20 0.32
FEN1 P39748 5/20 0.32
TGFBR1 P36897 2/20 0.32
MAPK14 Q16539 1/20 0.32
DHFR P00374 1/20 0.32
TDO2 P48775 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PDE10A Q9Y233 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PI4KA P42356 1/20 0.31
PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30462779 0.95 CHEK2 (0.32) PLGF12F11KLKB1PRSS1
Formic Acid SCHEMBL25299164 0.95 CHEK2 (0.32) PLGF12F11KLKB1PRSS1
SCHEMBL26067418 0.92 PDE10A (0.32) CHEK2ALOX5APFEN1TGFBR1DHFR
SCHEMBL25840713 0.88 PLG (0.37) PLGF12F11KLKB1PRSS1
SCHEMBL25260914 0.86 CHEK2 (0.31) CHEK2
Formic Acid SCHEMBL30462859 0.83 PLG (0.34) PLGF12F11KLKB1PRSS1
Formic Acid SCHEMBL25301010 0.83 PLG (0.34) PLGF12F11KLKB1PRSS1
SCHEMBL25259518 0.81 PDE10A (0.31) PDE10A
SCHEMBL30462824 0.81 PDE10A (0.31) PDE10A
SCHEMBL25840710 0.80 PLG (0.34) PLGF12F11KLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.